A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 7, 2007, Pages 2388-2395

  Cai, Lifeng ^a   Gochin, Miriam ^a,b  

^a Touro University California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; PEPTIDE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPETITIVE INHIBITION; FLUORESCENCE ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; SCREENING TEST; VALIDATION PROCESS;

ANTI-HIV AGENTS; BIOLOGICAL ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENCE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; MEMBRANE FUSION; MOLECULAR WEIGHT; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; REPRODUCIBILITY OF RESULTS; THERMODYNAMICS;

EID: 34447260888     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00150-07     Document Type: Article

References (52)

1. Reference deleted.
2. Buxser, S., and S. Vroegop. 2005. Calculating the probability of detection for inhibitors in enzymatic or binding reactions in high-throughput screening. Anal. Biochem. 340:1-13.
3. Caffrey, M., M. Cai, J. Kaufman, S. J. Stahl, P. T. Wingfield, D. G. Covell, A. M. Gronenborn, and G. M. Clore. 1998. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 17:4572-4584.
4. Cammack, N. 2001. The potential for HIV fusion inhibition. Curr. Opin. Infect. Dis. 14:13-16.
5. Chan, D. C., C. T. Chutkowski, and P. S. Kim. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA 95:15613-15617.
6. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
7. Chen, Y.-H., Y. Xiao, and M. P. Dierich. 2000. HIV-1 gp41: role in HIV entry and prevention. Immunobiology 201:308-316.
8. Chinnadurai, R., J. Munch, M. Dittmar, and F. Kirchhoff. 2005. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS 19:1919-1922.
9. Debnath, A. K., L. Radigan, and S. Jiang. 1999. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 42:3203-3209.
10. Doms, R. W., and J. P. Moore. 2000. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:F9-F13.
11. Eckert, D. M., and P. S. Kim. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777-810.
12. Eckert, D. M., V. N. Malashkevich, L. H. Hong, P. A. Carr, and P. S. Kim. 1999. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99:103-115.
13. Eckert, D. M., V. N. Malashkevich, and P. S. Kim. 1998. Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J. Mol. Biol. 284:859-865.
14. Ernst, J. T., O. Kutzki, A. K. Debnath, S. Jiang, H. Lu, and A. D. Hamilton. 2002. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed. Engl. 41:278-281.
15. Feng, B. Y., A. Shelat, T. N. Doman, R. K. Guy, and B. K. Shoichet. 2005. High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 1:146-148.
16. Frazier, R. A., A. Papadopoulou, I. Mueller-Harvey, D. Kissoon, and R. J. Green. 2003. Probing protein-tannin interactions by isothermal titration microcalorimetry. J. Agric. Food Chem. 51:5189-5195.
17. Frey, G., S. Rits-Volloch, X. Q. Zhang, R. T. Schooley, B. Chen, and S. C. Harrison. 2006. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc. Natl. Acad. Sci. USA 103:13938-13943.
18. Ghadiri, M. R., C. Soares, and C. Choi. 1992. A convergent approach to protein design. Metal ion-assisted spontaneous self-assembly of a polypeptide into a triple-helix bundle protein. J. Am. Chem. Soc. 114:825-831.
19. Gochin, M., R. K. Guy, and M. A. Case. 2003. A metallopeptide assembly of the HIV-1 gp41 coiled coil is an ideal receptor in fluorescence detection of ligand binding. Angew. Chem. Int. Ed. Engl. 42:5325-5328.
20. Gochin, M., V. Khorosheva, and M. A. Case. 2002. Structural characterization of a paramagnetic metal-ion-assembled three-stranded alpha-helical coiled coil. J. Am. Chem. Soc. 124:11018-11028.
21. Gochin, M., R. Savage, S. Hinckley, and L. Cai. 2006. A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41. Biol Chem. 387:477-483.
22. 1H NMR isotropic shifts from some methyl-substituted bipyridine complexes with Ni(II) and Co(II). Can. J. Chem. 59:1689-1700.
23. Hunter, R. J. 1991. Foundations of colloid science. Oxford University Press, New York, NY.
24. Ji, C., J. Zhang, N. Cammack, and S. Sankuratri. 2006. Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression. J. Biomol. Screen. 11:65-74.
25. Jiang, S., and A. K. Debnath. 2000. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem. Biophys. Res. Commun. 270:153-157.
26. Jiang, S., H. Lu, S. Liu, Q. Zhao, Y. He, and A. K. Debnath. 2004. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors. Antimicrob. Agents Chemother. 48:4349-4359.
27. Jiang, S., Q. Zhao, and A. K. Debnath. 2002. Peptide and non-peptide fusion inhibitors. Curr. Pharm. Design 8:563-580.
28. Jin, B. S., W. K. Lee, K. Ahn, M. K. Lee, and Y. G. Yu. 2005. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41. J. Biomol. Screen. 10:13-19.
29. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
30. Kilgore, N. R., K. Salzwedel, M. Reddick, G. P. Allaway, and C. T. Wild. 2003. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J. Virol. 77:7669-7672.
31. Kliger, Y., and Y. Shai. 2000. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J. Mol. Biol. 295:163-168.
32. Lieberman, M., and T. Sasaki. 1991. Iron(II) organizes a synthetic peptide into three-helix bundles. J. Am. Chem. Soc. 113:1470-1471.
33. Liu, S., L. Boyer-Chatenet, H. Lu, and S. Jiang. 2003. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41. J. Biomol. Screen. 8:685-693.
34. Liu, S., S. Jiang, Z. Wu, L. Lv, J. Zhang, Z. Zhu, and S. Wu. 2002. Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte. Life Sci. 71:1779-1791.
35. Liu, S., H. Lu, Q. Zhao, Y. He, J. Niu, A. Debnath, S. G. Wu, and S. Jiang. 2005. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim. Biophys. Acta 1723:270-281.
36. Liu, S., S. Wu, and S. Jiang. 2007. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Design 13:143-162.
37. Louis, J. M., I. Nesheiwat, L. Chang, G. M. Clore, and C. A. Bewley. 2003. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278:20278-20285.
38. Lu, F., S. Chi, D. Kim, K. Han, I. Kuntz, and R. Guy. 2006. Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. J. Comb. Chem. 8:315-325.
39. Lu, L., S. W. Liu, S. B. Jiang, and S. G. Wu. 2004. Tannin inhibits HIV-1 entry by targeting gp41. Acta Pharmacol. Sin. 25:213-218.
40. Markosyan, R. M., M. Xiuwen, M. Lu, F. S. Cohen, and G. B. Melikyan. 2002. The mechanism of Inhibition of HIV-1 env-mediated cell-cell fusion by recombinant cores of gp41 ectodomain. Virology 302:174-184.
41. McGovern, S., E. Caselli, N. Grigorieff, and B. Shoichet. 2002. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45:1712-1722.
42. McGovern, S., B. Helfand, B. Feng, and B. Shoichet. 2003. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46:4265-4272.
43. McGovern, S. L., and B. Shoichet. 2003. Kinase inhibitors: not just for kinases anymore. J. Med. Chem. 46:1478-1483.
44. Melikyan, G. B., R. M. Markosyan, H. Hemmati, M. K. Delmedico, D. M. Lambert, and F. S. Cohen. 2000. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151:413-423.
45. Mo, H., A. K. Konstantinidis, K. Stewart, T. Dekhtyar, T. Ng, K. Swift, E. Matayoshi, W. Kati, W. Kohlbrenner, and A. Molla. 2004. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. Virology 329:319-327.
46. Naicker, K. P., S. Jiang, H. Lu, J. Ni, L. Boyer-Chatenet, L.-X. Wang, and A. K. Debnath. 2004. Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[l,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo] -5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives. Bioorg. Med. Chem. 12:1215-1220.
47. Root, M., and H. Steger. 2004. HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. Design 10:1805-1825.
48. Root, M. J., M. S. Kay, and P. S. Kim. 2001. Protein design of an HIV-1 entry inhibitor. Science 291:884-888.
49. Shu, W., J. Liu, H. Ji, L. Radigen, S. Jiang, and M. Lu. 2000. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 39:1634-1642.
50. Sia, S. K., P. A. Carr, A. G. Cochran, V. N. Malashkevich, and P. S. Kim. 2002. Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. USA 99:14664-14669.
51. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
52. Zhang, J., T. Chung, and K. Oldenburg. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.